Health Yuan announced that Lizhu Group, a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to approve the YJH-12 injection to carry out clinical trials. YJH-012 injection is a novel siRNA drug jointly developed by Lizhu Group and Youjia Biomedical Technology Co., Ltd. The indication is gout. As of the announcement disclosure date, the total direct investment in R&D expenses of YJH-12 injection was approximately RMB 257.38,600. There are no micronucleic acid products with the same indications on the market in China.

Zhitongcaijing · 06/24/2025 07:41
Health Yuan announced that Lizhu Group, a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration to approve the YJH-12 injection to carry out clinical trials. YJH-012 injection is a novel siRNA drug jointly developed by Lizhu Group and Youjia Biomedical Technology Co., Ltd. The indication is gout. As of the announcement disclosure date, the total direct investment in R&D expenses of YJH-12 injection was approximately RMB 257.38,600. There are no micronucleic acid products with the same indications on the market in China.